Metzineres promotes communities that guarantee full access to the rights, well-being, and pleasure of womxn who are surviving violence, intersectional vulnerabilities, and that are affected by the war on drugs.

Metzineres promueve comunidades que garanticen el pleno acceso a derechos, bienestar y placer de las mujerxs, interseccionalmente vulnerabilizadas y atravesadas por la guerra contra las drogas.

Metzineres promeut des communautés qui garantissent le plein accès aux droits, au bien-être et au plaisir des femmes (cis et trans) et des personnes non conformes au genre qui survivent à la violence, aux vulnérabilités intersectionnelles et qui sont affectées par la guerre contre la drogue.

Metzineres 

We, the undersigned organisations, are deeply concerned about the drastic intensification of anti- drug operations in Sri Lanka leading to significant human rights violations.

On 17 December 2023 the Acting Inspector General of Police Deshabandu Tennekoon, with the endorsement of Minister of Public Security Tiran Alles, spearheaded an operation titled “Yukthiya”, with the stated aim of controlling “the drug menace”. The operation is ongoing as of 10 January 2024, with at least one thousand persons arrested daily.

This operation is unfolding in a context of already severe repression against persons who use or are suspected of using drugs, who suffer discrimination and stigma within the Sri Lankan criminal justice system and society.

Alongside the Sri Lankan police, members of the armed forces have been supporting this operation, during which several human rights violations have been reported. These violations include alleged arbitrary arrests, primarily against individuals from marginalised socio-economic communities; searches conducted without warrants or reasonable suspicion; and degrading treatment including strip searches in public as well as cavity searches. The searches and arrests have been televised, in violation not only of the right to privacy (and of basic human dignity) but also of a person’s right to be presumed innocent. According to lawyers, persons are being arrested even when no drugs are found in their possession, simply for having been arrested for drug offences or having been sent to compulsory rehabilitation in the past. The arrests of main livelihood earners and mothers have adversely impacted the ability of families to meet their basic needs during a time of economic crisis in Sri Lanka, and the wellbeing of children.

Persons are being arrested primarily under Section 54A of the Poisons, Opium and Dangerous Drugs Ordinance, an offence which is non-bailable. As a result, those arrested are bound to spend time (sometimes months) in pretrial detention, thereby exacerbating already poor conditions of imprisonment in an overburdened prison system. The Human Rights Commission of Sri Lanka has previously stated that the existing prison conditions and treatment of incarcerated persons are “inhumane and degrading.”At present, as per statistics issued by the Department of Prisons, the level of overcrowding of the prison system is at nearly 200% - with punitive drug policies playing a significant role: as of 2022, 63% of convicted persons were sentenced for drug-related offences.

The total reported number of arrests pursuant to operation Yukthiya has exceeded 29,000 as of 9 January 2024, while nearly 1,500 people are in administrative detention in police custody for further investigation.  At least 1,600 more persons have been sent for compulsory drug rehabilitation, in violation of several fundamental rights; including the right to the highest attainable standard of health, which includes the right to consent to and withdraw from medical treatment. “Drug treatment” in these centres is abstinence-based, essential harm reduction services are not available, and persons undergo severe withdrawal symptoms without any medical assistance while in detention. The use of violence to discipline and punish has been reported in at least two compulsory drug rehabilitation centres which are within the purview of the Bureau of the Commissioner General for Rehabilitation and are operated by the military, which is in itself a violation of international standards.

The UN Working Group on Arbitrary Detention in its statement at the conclusion of its visit to Sri Lanka in 2017 expressed concern regarding the involvement of military personnel in drug treatment and rehabilitation, the fact that strenuous physical exercise was the core component of compulsory drug treatment, and at the lack of trained professionals to monitor the health of people in detention. Furthermore, the statement highlighted the irregularities in the judicial process by which persons were sent to drug rehabilitation centres without a medical assessment.

More broadly, the UN Special Rapporteur on Torture has highlighted that by denying persons access to substitution therapies, states are subjecting “a large group of people to severe physical pain, suffering and humiliation, effectively punishing them for using drugs and trying to coerce them into abstinence.” The Special Rapporteur has further stated “forcible testing of people who use drugs without respecting their autonomy and their right to informed consent may constitute degrading treatment, especially in detention settings. States are obliged to respect the enjoyment of the right to health, including by refraining from using coercive medical treatment. The requirement of informed consent, including the right to refuse treatment, should be observed in administering any treatment for drug dependence.”

Since the 2016 UN General Assembly Special Session on drugs, there is international consensus on pursuing a holistic and health and human rights-based approach to drugs, which encompasses supply and demand reduction as well as harm reduction. The 2019 Ministerial Declaration on drugs – the current global drug policy document - as well as multiple resolutions of the UN General Assembly, the UN Commission on Narcotic Drugs, and the UN Human Rights Council reiterate and recommend a similar approach.

A punitive and militarised approach to drug control contravenes recognised international human rights standards and guidelines, is ineffective to protect individual and public health, and ultimately fails to make communities safer.

Africa Network of People Who Use Drugs (AfricaNPUD) (Africa)

Anti-Death Penalty Asia Network (ADPAN) (Asia)

Association for Humane Drug Policy (Norway)

Centre on Drug Policy Evaluation (CDPE) (Canada)

Centro de Estudios Legales y Sociales (CELS) (Argentina)

Corporación Acción Técnica Social (Colombia)

Correlation - European Harm Reduction Network (Europe)

Drug Harm Reduction Advocacy Network Nigeria (Nigeria)

Foreningen Tryggere Ruspolitikk /Safer Drug Policies (Norway)

GREA - Groupement Romand d'Etudes des Addictions (Switzerland)

Helsinki Foundation for Human Rights (Poland)

International Commission of Jurists (ICJ)

International Drug Policy Consortium (IDPC) (Global)

International Network of People who Use Drugs (INPUD) (Global)

Skoun, Lebanese Addictions Centre (Lebanon)

Zimbabwe Civil Liberties and Drug Network (Zimbabwe)

Sri Lanka: Stop abusive anti-drug operation and release those arbitrarily detained

Report presented at the 85th Session of the Committee on the Elimination of Discrimination against Women (CEDAW) 

This report describes the situation of women and gender diverse people
who use drugs and survive multiple situations of violence and vulnerability
in Spain. It was prepared by Metzineres, a non-profit cooperative based in
Barcelona, Spain, and the International Drug Policy Consortium (IDPC).
Information provided is based on research conducted by civil society
organizations and official sources. The 435 participants of Metzineres have
also provided their testimony, which has been systematized through their
own database, along with indicators based on the elements that are
important to them.

We examined the interconnected situations of vulnerability, multiple
discriminations, and violations of rights that they endure: problems related
to drug use, homelessness, sex work or sex for survival, migration
experience and/or irregular administrative situations, mental health
problems, violence, criminalization, etc. There are severe barriers to
accessing social and health care networks, the drug addiction networks,
and domestic violence networks, as well as the Spanish justice system
itself.

The policies implemented by the State to date are insufficient to address
this issue. It is imperative that immediate measures are taken in order to
ensure their protection, adequate support, access to rights, and to end
their criminalization.

We ask the Committee to urge the Government of Spain to adopt
reasonable measures to eliminate the systematic discrimination,
criminalization and violence suffered by women and gender diverse people
who use drugs and are in multiple and interconnected situations of
vulnerability.

On the situation of women and gender-diverse people who use drugs surviving multiple situations of violence and vulnerability in Spain - Shadow report

In 2020, Peter Krykant established the first grassroots mobile safer consumption site, reliant almost entirely on volunteer labour and providing as safe a venue as possible for Glasgow’s most precarised drug users. Aura Roig is the Director of Metzineres, a community hub founded in 2017 as the first integrated harm reduction programme by and for women and non-binary people who use drugs in Catalonia.

Drawing on these experiences, this wide-reaching conversation with Juan Fernández Ochoa will look at mutual aid practices based on the lived and living experiences of people who use drugs. Challenging the idea that all we can do to respond to structural violence and neglect is ask the state for services, this conversation will instead contemplate what kinds of [systemic] change are made possible when we prioritise people supporting each other.

Gesturing to what is possible: Drugs users supporting each other

To: Ms Ghada Waly, Executive Director, United Nations Office on Drugs and Crime

Subject: Open letter on UNODC statement on International Human Rights Day 2021

We urge you to mark International Human Rights Day 2021 by calling on Member States to change drug policies and practices that violate human rights and perpetuate inequality and discrimination.

We are writing to you ahead of International Human Rights Day 2021, which will take place on the 10th December amidst escalating global demands for the reform of laws and practices that entrench racial discrimination and social inequality, including drug policies. Last year, IDPC – together with dozens of other civil society and community organisations – called on you to issue a statement on International Human Rights Day urging Member States to change drug laws and practices that undermine health and human rights. A year later, we ask you to seize this day as an opportunity to show UNODC´s alignment with other UN entities in calling for an end to drug policies and practices that perpetuate inequality and discrimination, and violate human rights.

For decades, punitive drug policies have driven widespread human rights abuses, as has been amply documented by the UN. These include the death penalty for drug offences; extrajudicial killings; arbitrary detention, often masquerading as ‘rehabilitation’; the denial of access to life-saving harm reduction services; widespread barriers to accessing controlled medicines for pain relief; the criminalisation of people who use drugs, subsistence farmers and others groups in situations of vulnerability; corporal punishment; and mass incarceration. In all of these cases, draconian drug policies have disproportionately affected people marginalised on the basis of their gender, race, ethnicity, and economic status, thus entrenching inequality and discrimination.

Along 2021, a broad range of UN entities called on Member States to reform drug policies with discriminatory outcomes. In June 2021, the UN Working Group on Arbitrary Detention released a landmark study on arbitrary detention and drug polices, which found that ´

the war on drugs may be understood to a significant extent as a war on people. Its impact is often greatest on those who are poor, but also frequently overlaps with discrimination in law enforcement directed at vulnerable groups

´. At the same time, the UN High Commissioner for Human Rights published a new ‘Agenda towards transformative change for racial justice and equality´, highlighting that ´

The discriminatory application of criminal law must be tackled at every stage, including by reforming drug-related policies

´. The High Commissioner´s proposal led to Human Rights Council Resolution 47/21, which contains key commitments to uproot systemic racism in the law enforcement and criminal justice systems. The Political Declaration on HIV and AIDS, adopted in June 2021, also showcased the international community´s commitment to ending inequalities as a step towards ending AIDS. Lastly, the new UN system Common Position on Incarceration, led by UNODC in partnership with other UN entities, notes ‘

the overrepresentation of minority and marginalized groups among prisoners, many of whom are charged with petty and nonviolent offences

support reform efforts aimed at ensuring proportionate and individualized sentencing and alternatives to conviction or punishment in appropriate cases, including for minor drug-related offences

These various commitments emerging across the United Nations are aligned with the 2018 Chief Executives Board’s UN System Common Position on drug-related matters, which makes clear that ‘

should be designed and implemented by States in accordance with their human rights obligations

’, and commits all UN agencies, including UNODC, to support drug policies ‘

that put people, health, and human rights at the centre

Similar human rights concerns have been highlighted in the just-released Global Drug Policy Index, which measures and ranks the national drug policies of 30 countries according to how well they align with the UN system Common Position on Drugs and its Task Team report of March 2019.

The theme of the 2021 International Human Rights Day is ‘Equality: Reducing inequalities, advancing human rights’, and is aimed at ´

addressing and finding solutions for deep-rooted forms of discrimination that have affected the most vulnerable people in societies

´. As such, it presents a crucial opportunity for UNODC to align itself with other UN entities in calling for the end of policies that perpetuate inequality and discrimination, while highlighting its commitment to the promotion of human rights, in line with the UN system Common Positions.

It is in this context that we urge you to issue a strong statement on International Human Rights Day, calling on states to change the drug laws, policies and practices that violate health and human rights, and entrench inequality. To be credible, such a statement should explicitly acknowledge the disproportionate impact of drug laws and drug control on people marginalised on the basis of their gender, race, ethnicity, and economic status, and urge Member States to:

Abolish the death penalty in all circumstances. Imposing capital punishment for drug offences has been found to be contrary to international human rights law by the Human Rights Committee, and the Human Rights Council.

Put an immediate end to extrajudicial killings committed in the name of drug control, as has been repeatedly called for by the Human Rights Council and UN human rights experts.

Permanently close compulsory drug detention centres, including those that masquerade as ‘rehabilitation’, and implement voluntary, evidence-informed, and rights-based health and social services, as recently called for by sixteen UN agencies, including UNODC.

Stress the urgent need to provide accessible, affordable, and adequately funded harm reduction services in community and closed settings, to fulfil the right to health and the right to life of people who use drugs, as demanded by several UN human rights bodies and experts. This is also central to UNODC’s core role as lead UNAIDS co-sponsor regarding prisons and HIV amongst people who use drugs.

Take immediate measures to address prison overcrowding, as already recommended by UNODC and the UN High Commissioner for Human Rights in the wake of the COVID-19 pandemic, by promoting alternatives to incarceration, and ensuring proportionate sentencing for all drug offences, including by taking into account mitigating factors – in line with the basic principle that prisons should only be used as a last resort in all circumstances.

Ensure that people who use drugs are not subject to arbitrary detention, torture, or ill-treatment – whether in state custody or public or private drug services. While under detention, people with a drug dependence or health problems associated with their drug use must be offered evidence-based treatment, harm reduction and other drug services on a strictly voluntary basis.

Promote the end of all punishment for drug use, and drug possession and cultivation for personal use, as permitted within the three drug control conventions. Such policy shifts will help to end the stigma, criminalisation, and exclusion faced by people who use drugs, and to facilitate access to health and social services, as called for by the UN system Common Position, UNAIDS, and UN human rights bodies.

Make sure that drug policies incorporate a gender-sensitive perspective. This should be done by tailoring drug services to the specific needs of women, and by ensuring that criminal laws take into account the circumstances of women involved in drug offences, as most of them come from backgrounds of poverty, marginalisation, and oppression.

Clearly outline the ways in which UNODC will work to achieve these changes, and the measures being taken to ensure that human rights are effectively embedded as a core strand for all of the Office’s work.

As the lead UN agency in drug-related matters, UNODC has the responsibility to promote drug policies that respect, protect, and fulfil human rights, in a way that is consistent with the standards developed by the UN system, and in line with the commitments set in the UN system Common Positions on drugs and on incarceration. A strong statement in the forthcoming International Human Rights Day would be an important and welcome step to signal UNODC’s unequivocal commitment.

We look forward to discussing these concerns and recommendations with you.

NGOs urge UNODC's Executive Director to mark Human Rights Day with a call to reform drug policies that entrench inequality

Metzineres provides a safe haven for womxn who use drugs who are also surviving violence in Barcelona. They are not passive victims to be rescued – we can learn a lot from them about community empowerment. Watch our new video produced together with INPUD!

Repressive drug policies fuel violence in multiple ways. Directly, by punishing people who buy or sell drugs, and indirectly, by creating a violent black market for illegal drugs. Police repression usually targets poor, marginalised communities. Those people who are already vulnerable based on their gender, sexual orientation, or race, become even more vulnerable as a consequence of the fear of criminalisation and discrimination.

Our new video features Metzineres, an organisation in Barcelona that organises communities of womxn (here the ‘x’ means that they include trans and non-binary people) who use drugs to recover from systemic violence and to fight back.

They provide safe environments for the survivors of violence to escape street environments where they are often abused and attacked. They provide shelters to sleep in and wash their clothes, and safer spaces for consuming their drugs, without the risk of infections and overdose deaths. They also offer psychosocial support for those who struggle with homelessness, mental health issues, and family problems, as well as putting on creative community activities, dance, yoga, cosmetics etc to make them feel that they belong.

Metzineres is more than a service provider – they are a community, with more than 300 members. Half of them are homeless, 30% have been imprisoned before.

These womxn are not passive victims to be rescued – they are creative and resilient human beings. We can learn a lot from them about how we should stand up for each other.

This video was produced together with INPUD – The International Network of People who Use Drugs.

: Carmen Molina | @carmencapta | carmencapta.com


Metzineres: From survival to fighting back

Women who use drugs are exposed to higher rates of violence than other women. This violence includes, (but is not limited to) rape, sexual harassment, extortion, loss of child custody, imprisonment for mere personal possession, extra judicial killing, capital punishment and penalisation for drug use in pregnancy. Prohibition either directly causes or greatly exacerbates conditions for all of these violations. Gender-based violence cannot be eliminated if those most affected are not directly and meaningfully involved at all levels in relevant policy and programming.

Women who use drugs are boldly stepping out to take their place in the women’s movement and efforts to stop gender-based violence. Collectively we and our allies call for governments to end the gendered, failed and murderous policy of drug prohibition.

The elimination of violence against women who use drugs (EVAWUD) - 2020 campaign report

As we approach the 10th anniversary of the adoption of the United Nations Rules for the Treatment of Women Prisoners and Non-custodial Measures for Women Offenders (the Bangkok Rules), we, the undersigned, express alarm at the increase in the global female prison population by around 100,000 since the adoption of the Rules – which aim to reduce the imprisonment of women – and the continuing discrimination and abuse experienced by women in criminal justice systems.

The number of women in prison is rising at an alarming rate, even though women are typically convicted of low-level non-violent crimes. Women are disproportionately impacted by punitive drug policies and often commit crimes in poverty to keep themselves and their families alive. Many find themselves in prison as a direct result of discrimination.

As a minority in prisons, representing on average 2-9% of national prison populations, women are often not provided with access to programmes and services to support their rehabilitation that address their specific needs and characteristics. There is also a mental health crisis among women in prison, with up to 80% living with an identifiable mental illness, which has been compounded by measures related to preventing and addressing the spread of COVID-19.

Women around the world continue to face threats to their dignity and humanity in detention. They are often unable to access adequate healthcare and are at particularly high risk of sexual assault and humiliation in prison. In some countries, women are even restrained during labour and birth or placed in solitary confinement whilst pregnant or caring for an infant child.

Protect the human rights of women in the criminal justice system - Joint call to action

By Sam Shirley, Aura Roig, Naomi Burke-Shyne, Colleen Daniels, and Robert Csak - Harm Reduction Journal

There are an estimated 3.2 million women who inject drugs worldwide, constituting 20% of all people who inject drugs. Accounting for the concealing effects of criminalisation, gender power imbalances and stigma, this number is likely to be an underestimate. The limited data that are available suggest that women who inject drugs are at greater risk of HIV and viral hepatitis acquisition than men who inject drugs. This increased vulnerability is a product of a range of environmental, social and individual factors affecting women, which also affect their ability to engage in health promoting services such as harm reduction.

Health inequities occur where there are preventable differences between groups in access to services and resources that improve health outcomes. Women are demonstrably subject to health inequities with regard to access to harm reduction services. Despite a clear need for harm reduction services for women, they continue to be dominated by “masculinist” concerns and do not meet women’s needs, and the literature indicates that women who use drugs are rarely adequately represented in design and evaluation of harm reduction services.

In Europe, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) indicates women make up approximately a quarter of all people with drug dependence and around one-fifth of all entrants to drug treatment in Europe. EMCDDA reports women are particularly likely to experience stigma and economic disadvantage and to have less social support, among other factors.

A number of subgroups of women who use drugs have special needs. These subgroups, which often overlap, include pregnant and parenting women; women involved in sex work, who may often experience violence and stigma; women from ethnic minorities; women who may have been trafficked; and women in prison.

This paper builds on previous literature reviews that have examined the relationship between drug use and HIV among women, treatment effectiveness among women, stigma faced by women who use drugs, and drug use and intimate partner violence. It seeks to build on this body of work by examining the literature on women and harm reduction services globally, with the specific aim of identifying the key barriers standing in the way of women’s access to these services. The paper categorises the key barriers under four intersecting themes: stigma and structural violence, gender-based violence, criminalisation, and a lack of female-specific services, and highlights examples of each from Europe. It further analyses the evidence gathered in a qualitative study in Barcelona to determine to what extent barriers are evident in that context.

Women and barriers to harm reduction services: A literature review and initial findings from a qualitative study in Barcelona, Spain

The following letter was drafted by a coalition of 29 civil society organisations and community networks in the European Union. The letter urges the German Presidency to propose to the EU Horizontal Working Party on Drugs (HDG) that the current draft EU Agenda and Action Plan on Drugs 2021-2025 be rejected, and measures are taken to ensure an appropriate and inclusive strategic development process for the next EU drugs strategy.

We are writing regarding the proposed EU Agenda and Action Plan on Drugs 2021-2025, published by the European Commission on 24 July 2020 (the “2021-25 EU Drugs Agenda”, or the “Agenda”). We have serious concerns regarding both the process for its development as well as with the substance of the document and urge the German Presidency to propose to the EU Horizontal Working Party on Drugs (HDG) that this draft cannot be accepted, and to outline an appropriate and inclusive strategic development process for the next EU drugs strategy.

The formulation of the 2021-25 EU Drugs Agenda through a unilateral Communication of the European Commission without consultation with EU Member States and other relevant EU actors, including civil society is deeply problematic. If the HDG accepts this document as it stands, a worrying procedural precedent will be set. To date, the ‘EU’s drugs strategies and action plans are developed through a rigorous process that allows Member States to work together on the development of strategic approaches. This involves a series of negotiations, evaluations and compromises so that consensus can be reached in the form of a new strategy document.’ The 2021-25 EU Drugs Agenda appears to be the result of a hasty, opaque and non-participatory policy-making process, and represents a drastic departure from agreed EU policies. The lack of appropriate consultation and engagement inevitably means that the different experiences and views of EU Member States and other relevant EU actors have less weight in the new document. It fails to adopt a balanced, integrated, and multidisciplinary approach to drug matters; it is not rooted on human rights, public health, and the key international drug policy documents; and it envisages a diminished role for civil society and affected communities.

The European Union has been a global leader in advancing a balanced, integrated, and multidisciplinary approach to drug policies. The 2005 and 2013 EU Drugs Strategies established a consolidated framework that has become a ‘central guiding model’ for national-level drug strategies across the EU. However, the 2021-25 EU Drugs Agenda proposes -in its own words- a ‘paradigm-shift’. It disproportionately focuses EU policy on law enforcement and supply control, to the detriment of the priority previously given to public health, human rights, international cooperation, and scientific research and evaluation. If implemented, it will signal a diminished support for evidence-based drug treatment and harm reduction services, and it will weaken the voice of the EU in international drugs fora, where it has been a key global actor in defending the balanced, rights-based approach adopted by the 2016 UNGASS Outcome Document.

In spite of the EU’s commitment to seek the ‘active and meaningful participation and involvement of civil society’ in the ‘development and implementation of drug policies’, the participation of civil society in the preparation of the 2021-25 Drugs Agenda has been deeply flawed. European NGOs were only allowed to provide input to the Agenda with the publication of the Road Map, on 10 June 2020, with no other opportunity to feed in the process, besides a call between the Commission and certain CSFD members in April. It should be borne in mind that the Road Map is a document of just over two pages that does not allow for a genuine understanding of, or feedback on, the Agenda. No draft of the Agenda was ever shared.

Furthermore, the European Commission disregarded the overwhelming majority of the 27 submissions sent by European NGOs, which urged the EU to retain the balanced and multidisciplinary approach that characterized the 2005 and 2013 EU Drugs Strategies. The fact that the deadline for submitting feedback was 15 July 2020, a mere nine days before the publication of the Communication, suggests that the consultation was not undertaken in the spirit of genuine inquiry, and that the Agenda was at least near completion when the Road Map was published.

Crucially, although the external evaluation of the 2013 EU Drugs Strategy was finalised in April 2020, the evaluation was not published or otherwise shared with civil society until three months later, on 24 July 2020, thus depriving stakeholders of crucial information when providing feedback to the Road Map. This is important, as there would appear to be a significant disconnect between the Agenda and the external evaluation. For instance, the evaluation consistently found that the 2013 Strategy had ‘sparked a considerable amount of progress’ in the cross-cutting areas of coordination, international cooperation, and monitoring, research and evaluation, which are precisely the areas now removed from the Agenda.

In addition to the grave concerns regarding the process and procedure, we felt it is important to bring your attention the key flaws in the draft Agenda:

. Although the Agenda explicitly claims to seek an ‘integrated, balanced, and multidisciplinary approach’ to drug policies, the draft is not balanced, as over half of its eight priority areas concern security and supply control interventions, with the rest distributed between prisons, prevention, treatment, and harm reduction. Public health measures aimed at reducing the harms that can be associated to drug use have been relegated from the first priority of the 2013 Drugs Strategy to the end of the new Agenda. The cross-cutting themes of coordination, international cooperation, and information and research, which have been successfully developed since 2013 to materialise the multidisciplinary and integrated approach, have been dropped. The many references to the balanced approach across the operative parts of the 2013 Strategy, for instance as the basis for increased coordination across all actors, interventions at the CND, and international cooperation, have also disappeared.

Deprioritising human rights and public health.

 Human rights have practically disappeared from the draft Agenda, which contains no reference to the relevant international or regional human rights instruments, including the Universal Declaration of Human Rights. Furthermore, there is no mention of the International Guidelines on Human Rights and Drug Policy, a critical document developed with the leading support of Germany that lays down, for the first time, a set of clear and comprehensive international standards for articulating rights-based responses to illegal drug economies. In contrast, the 2013 EU Drugs Strategy explicitly referred to the Universal Declaration of Human Rights and the European Convention of Human Rights, amongst others, and human rights were mentioned several times in the section on international cooperation. Public health has been relegated from the first policy field in the 2013 Strategy to the last priority areas of the Agenda, and has been replaced by ‘drug-related security’ as the first goal of the document.

Dropping support for key international documents.

 Equally surprising is the little attention paid to the 2016 UNGASS Outcome Document - only a footnote in the preambular part of the Agenda, and a mention in the Action Plan, outside its priority areas -, even though it has been consistently described by the EU as ‘the most comprehensive policy agreement of the international community and a milestone in the discussions on international drug policy’. It is also inexplicable that the Agenda would completely fail to reference the 2018 UN System Common Position on Drugs, a watershed document championed by the EU and EU Member States, as it establishes for the first time a coherent position across all UN entities on key topics like decriminalisation and harm reduction.

Reducing the space for civil society and people who use drugs.

 Whereas the 2013 EU Drugs Strategy contained a commitment to promote and encourage ‘the active and meaningful participation and involvement of civil society’, the EU Drugs Agenda only mentions ‘engagement’ with the CSFD. Involvement with civil society beyond the CSFD has been omitted, and there is no reference to engaging with people who use drugs and clients of drug services, which the 2013 Strategy did.

Weakening the external dimensions of drug policy.

 The 2021-25 Drugs Agenda risks weakening the external action of the EU in bilateral and multilateral drugs fora, as it does not set clear guidelines for EU coordinated intervention, and it does not provide strong support for the key international documents that the EU has been forcefully defending and promoting in the last years. For instance, the Agenda does not provide any concrete principle or guideline for intervening at the CND, even though it is arguably the centre of the international drug control system, and the role of the EU there is more important than ever. This contrasts greatly with the 2013 Drugs Strategy, which committed the EU to a ‘strong voice’ in the Commission on Narcotic Drugs, with the aim of promoting the balanced approach. Another case in point is the only reference to alternative development in the whole Agenda, which can be found under the heading ‘dismantling drug production’, and is not deemed to warrant even one of the 24 priority areas set in the document. This is especially surprising considering that the 2018 Council Conclusions adopted exclusively on this topic committed the EU to a ‘leading role (…) in the funding and implementation of alternative development’, and stated clearly that the success of alternative development goes ‘beyond an exclusive focus on illicit drug crop monitoring’.

 In spite of the EU’s leading role in fostering scientific knowledge and research on drug markets and drug use through the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the 2021-25 EU Drugs Agenda has dropped the cross-cutting theme on monitoring, research and evaluation, and science-based drug policies are scarcely mentioned in the operative parts of the document. Again, this makes a striking contrast with the 2013 Drugs Strategy, which featured a whole theme on research and evaluation for ‘a better understanding of all aspects of the drug phenomenon’, and provided a role for the EMCDDA in supply reduction, international cooperation, and the overall implementation of the document, among others.

 Although the 2021-25 Drugs Agenda explicitly seeks to reduce drug-related stigma, the European Commission press release accompanying the publication of the proposed Agenda was deeply stigmatising, as it puts drug policies at the same level as child abuse and firearms trafficking. Furthermore, the Agenda contains some instances of stigmatising language (‘substance abuse’ and ‘substance misuse’) that did not exist in the 2013 Drugs Strategy.

In light of the above and following established practices for the development of previous EU drugs strategies, we urge you, as the Council Presidency, to take political leadership and encourage the HDG to reject the draft proposed by the European Commission. A new process for strategy development should ensure that the new document reflects in a balanced manner the existing EU and the latest international commitments (in particular the 2016 UNGASS Outcome Document), the views of the EU Member States and all the relevant actors within the EU institutions, and engages meaningfully with civil society.

We would also be grateful if you could share this letter with your HDG colleagues before the 9 September meeting.
We remain at your disposal for any further discussion on this matter, and look forward to our continued cooperation on this and other topics during the German Presidency.

Metzineres

Region

Translations

Related Content